Digest Network Come funziona
Network
/
Società
Ar
Non verificato

Arrowhead Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

73 comunicati stampa

Guarda tutti i comunicati
24/02/2026
Eventi
Web e Social Network
Farmaceutica
Scienza
Salute
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Farmaceutica
Oncologia
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/01/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Industria
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
20/01/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Mercato azionario
Titoli e azioni
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Salute
Farmaceutica
Finanza
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Web e Social Network
Industria
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
05/01/2026
Industria
Salute
Biotecnologia
Farmaceutica
Medicina - Varie
Sanità
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
23/12/2025
Eventi
Fiere
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0